 |
PDBsum entry 2b53
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.11.22
- cyclin-dependent kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Bioorg Med Chem Lett
11:1157-1160
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Quinazolines as cyclin dependent kinase inhibitors.
|
|
T.M.Sielecki,
T.L.Johnson,
J.Liu,
J.K.Muckelbauer,
R.H.Grafstrom,
S.Cox,
J.Boylan,
C.R.Burton,
H.Chen,
A.Smallwood,
C.H.Chang,
M.Boisclair,
P.A.Benfield,
G.L.Trainor,
S.P.Seitz.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Quinazolines have been identified as inhibitors of CDK4/D1 and CDK2/E. Aspects
of the SAR were investigated using solution-phase, parallel synthesis. An X-ray
crystal structure was obtained of quinazoline 51 bound in CDK2 and key
interactions within the ATP binding pocket are defined.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.Sopková-de Oliveira Santos,
P.Verhaeghe,
J.F.Lohier,
P.Rathelot,
P.Vanelle,
and
S.Rault
(2008).
Nitrated isomers of 2-(trichloromethyl)quinoline.
|
| |
Acta Crystallogr C,
64,
o441-o444.
|
 |
|
|
|
|
 |
J.Sridhar,
N.Akula,
and
N.Pattabiraman
(2006).
Selectivity and potency of cyclin-dependent kinase inhibitors.
|
| |
AAPS J,
8,
E204-E221.
|
 |
|
|
|
|
 |
P.Dobes,
M.Otyepka,
M.Strnad,
and
P.Hobza
(2006).
Interaction energies for the purine inhibitor roscovitine with cyclin-dependent kinase 2: correlated ab initio quantum-chemical, DFT and empirical calculations.
|
| |
Chemistry,
12,
4297-4304.
|
 |
|
|
|
|
 |
Z.Kríz,
M.Otyepka,
I.Bártová,
and
J.Koca
(2004).
Analysis of CDK2 active-site hydration: a method to design new inhibitors.
|
| |
Proteins,
55,
258-274.
|
 |
|
|
|
|
 |
I.R.Hardcastle,
B.T.Golding,
and
R.J.Griffin
(2002).
Designing inhibitors of cyclin-dependent kinases.
|
| |
Annu Rev Pharmacol Toxicol,
42,
325-348.
|
 |
|
|
|
|
 |
M.Knockaert,
P.Greengard,
and
L.Meijer
(2002).
Pharmacological inhibitors of cyclin-dependent kinases.
|
| |
Trends Pharmacol Sci,
23,
417-425.
|
 |
|
|
|
|
 |
P.L.Toogood
(2002).
Progress toward the development of agents to modulate the cell cycle.
|
| |
Curr Opin Chem Biol,
6,
472-478.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |